Potent anti-tumour responses were observed in mice by incorporating CpG-ODN and anti-CD40 agonist antibody into liposomal carriers, with elimination of systemic toxic side effects achieved by focused sequestration in the TME [89]. This evidence concerns the gene CD40 and neoplasm.